CytoSorbents Corp., a Monmouth Junction-based immunotherapy company, announced on Monday it has appointed Efthymios N. Deliargyris as chief medical officer, effective May 1.
Deliargyris, who has more than 19 years of experience in the industry and academic medicine, most recently served as the chief medical officer of PLx Pharma. He also spend time as vice president, European medical director and global medical lead, acute cardiovascular care at The Medicines Co.
“I am very excited about joining this talented executive team during a time of tremendous progress as evidenced by FDA emergency use authorization of CytoSorb for critically-ill COVID-19 patients, and also FDA breakthrough designation for removal of ticagrelor during on-pump emergent and urgent cardiothoracic surgery. Whether silencing the cytokine storm or eliminating the risk of life-threating bleeding, CytoSorb is a game-changer with the potential to save thousands of lives and millions of healthcare dollars. We plan to design and execute a world-class clinical trial program and generate the necessary data to support regulatory approvals and establish CytoSorb as a life-saving therapy in multiple indications in the intensive care unit and cardiac surgery,” Deliargyris said.
“We are thrilled to have Efthymios join CytoSorbents to lead worldwide clinical activity in critical care and cardiac surgery applications during this exciting chapter at our company. His extensive expertise in cardiology, interventional cardiology, and the treatment of complications of critical illnesses such as shock, through many years of clinical practice, clinical trial research, and industry focus, make him well-suited for this task,” Dr. Phillip Chan, CEO of CytoSorbents said.
